Lupin is reportedly planning to acquire brands in the US markets, in order to sustain growth levels of up to 25% in the current fiscal. It has decided to introduce 20-25 products every year for the next couple of years in the US market. The entity has filed 21 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (USFDA) in 2012-13 financial year and received 14 approvals.
The company’s net profit grew by 56.70% at Rs 1260.43 crore for the year ended March 31, 2013 as compared to Rs 804.37 crore for the year ended March 31, 2012. Its total income has increased by 32.61% to Rs 7145.82 crore for the year from Rs 5388.32 crore for the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1782.00 |
| Dr. Reddys Lab | 1272.75 |
| Cipla | 1388.75 |
| Zydus Lifesciences | 1109.05 |
| Lupin | 2270.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: